Skip to content

Paul Glue

28 papers in the library · 619 citations · publishing 2015-2026

Papers

Sort Most recent Most cited

Effects of low dose ibogaine on subjective mood state and psychological performance.

Journal of Ethnopharmacology August 2, 2016 Bridget Forsyth, Liana Machado, Tim Jowett et al. 35 citations

Root bark from Tabernanthe iboga has been used traditionally in West Africa as a psychoactive substance in religious rituals. In smaller doses it is reported anecdotally to have stimulant properties. To evaluate the influence of a single 20mg ibogaine dose on psychological variables reflecting subjective mood state and a range of cognitive functions. 21 healthy male volunteers received single...

Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers.

Journal of clinical pharmacology June 1, 2015 Paul Glue, Helen Winter, Kira Garbe et al. 39 citations

Conversion of ibogaine to its active metabolite noribogaine appears to be mediated primarily by CYP2D6. We compared 168 hours pharmacokinetic profiles of both analytes after a single oral 20 mg dose of ibogaine in 21 healthy subjects who had been pretreated for 6 days with placebo or the CYP2D6 inhibitor paroxetine. In placebo-pretreated subjects, ibogaine was rapidly converted to noribogaine....

Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability.

Journal of clinical pharmacology February 1, 2015 Paul Glue, Michelle Lockhart, Fred Lam et al. 61 citations

Noribogaine is the active metabolite of the naturally occurring psychoactive substance ibogaine, and may help suppress withdrawal symptoms in opioid-dependent subjects. The objectives of this Phase I study were to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of noribogaine. In this ascending single-dose, placebo-controlled, randomized, double-blind,...